The impact of active herpes simplex virus infection on human immunodeficiency virus load

Journal of Infectious Diseases

Volumn 176, Issue 3, 1997, Pages 766-770

  Mole, Larry ^a   Ripich, Stefan ^a   Margolis, Dan ^a   Holodniy, Mark ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; GAG PROTEIN; MESSENGER RNA; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPIDEMIC; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS TITRATION; VIRUS TRANSCRIPTION;

EID: 0030852677     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517297     Document Type: Article

References (17)

1. Gendelman HE, Phelps W, Feigenbaum L, et al. Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci USA 1986;83:9759-63.
2. Golden MP, Sunyoung K, Hammer HM, et al. Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis 1992;166:494-9.
3. Mosca JD, Bednarik DP, Raj NBK, et al. Herpes simplex virus type 1 can reactivate transcription of latent human immunodeficiency virus. Nature 1987;325:67-70.
4. Heng MCY, Heng SY, Allen SG. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994;343:255-8.
5. Mellors J, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
6. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologie markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
7. Bush CE, Donovan RM, Markowitz NP, Kvale P, Saravolatz LD. A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. J Acquir Immune Defic Syndr 1996;13:23-6.
8. Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis 1996;174:401-3.
9. Michael N, Whalen C, Johnson J, et al. HIV-1 viral load dynamics in a longitudinal study of HIV-1 infected patients with and without active pulmonary tuberculosis [abstract WeB414]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, BC). Vancouver: XI International Conference on AIDS Society, 1996:27.
10. Kovacs JA, Baseler M, Dewar RJ, et al. Increase in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995;332:567-75.
11. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-30.
12. Brichacek B, Swindells S, Janoff EN, Pirruccello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996;174:1191-9.
13. Winters MA, Tan LB, Katzenstein DA, Merigan TC. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcription polymerase chain reaction. J Clin Microbiol 1993;31:2960-6.
14. Riddler SA, Holodniy M, White RA, et al. Diurnal and within patient variation of HIV viral load, [abstract 256]. In: 3rd Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1996:100.
15. Schaker T, Shaughnessy M, Barnium G, Corey L. Reactivation of HSV-2 in HIV infected persons is associated with increased levels of plasma HIV RNA [abstract 1235]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:248.
16. Semple M, Loveday C, Weller I, Tedder R. Direct measurement of viremia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J Med Virol 1991;35:38-45.
17. Manoff SB, Farzedegan H, Munoz A, et al. The effect of latent Mycobacterium tuberculosis infection on human immunodeficiency virus (HIV) disease progression and HIV RNA load among injecting drug users. J Infect Dis 1996;174:299-308.